CTAG1B: A Potential Drug Target and Biomarker (G1485)

Target Name: CTAG1B

NCBI ID: G1485

CTAG1B

CTAG1B: A Potential Drug Target and Biomarker

CTAG1B (CTAG1 gene) is a gene that encodes a protein known as CTAG1B. CTAG1B is a member of the BTK (Bruton-Turner) gene family, which is known for their role in the development and maintenance of hematological malignancies, such as leukemia and lymphoma. The BTK gene family has been implicated in the development of many other types of cancer, including melanoma, breast cancer, and colorectal cancer.

The CTAG1B gene was first identified in 2007 and has since been shown to encode a protein that is expressed in a variety of tissues and cells, including blood cells, lymphocytes, and solid tumors. The protein produced by the CTAG1B gene has been shown to have multiple functions, including promoting the growth and survival of cancer cells, inhibiting the apoptosis (programmed cell death) of cancer cells, and modulating the immune response to cancer cells.

One of the most promising aspects of CTAG1B is its potential as a drug target. The BTK gene family has been identified as a potential drug target in numerous studies, due to its involvement in the development and maintenance of many types of cancer. The CTAG1B protein has also been shown to be involved in the regulation of the blood cell development and in the immune response, making it a potentially attractive target for drug development.

In addition to its potential as a drug target, CTAG1B has also been shown to be a potential biomarker for cancer. The CTAG1B protein has been shown to be expressed in a variety of tissues and cells, including cancer cells, which makes it a potentially useful biomarker for the diagnosis and monitoring of cancer. Additionally, the expression of CTAG1B has been shown to be regulated by a variety of factors, including DNA methylation and histone modification, which may provide insight into its potential as a biomarker for cancer.

Another promising aspect of CTAG1B is its role in the regulation of the immune response. The CTAG1B protein has been shown to be involved in the regulation of T cell development and function, which is important for the immune response to cancer cells. Additionally, the CTAG1B protein has been shown to be involved in the regulation of the production of antibodies, which may be useful for the development of cancer vaccines.

In conclusion, CTAG1B is a gene that encodes a protein with multiple functions, including promoting the growth and survival of cancer cells, inhibiting the apoptosis of cancer cells, and modulating the immune response to cancer cells. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the role of CTAG1B in the development and progression of cancer.

Protein Name: Cancer/testis Antigen 1B

The "CTAG1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTAG1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets